Precision Medicine in AML: An Abundance of Options
By Amer Zeidan, MBBS, MHS, Harry Erba, MD, Courtney DiNardo, MD, MSCE, Maximilian Stahl, MD - Last Updated: December 31, 2024In this continuation of the roundtable series on acute myeloid leukemia (AML), experts delve deeper into the evolving treatment landscape, focusing on the transformative role of targeted therapies. Led by Amer M. Zeidan, MBBS, of Yale School of Medicine, the discussion highlights emerging novel agents and their potential to refine personalized treatment strategies. The panel examines the mechanisms, clinical applications, and challenges of incorporating these innovations into AML care.
Advertisement
Post Tags:ASH 2024: AML
Advertisement
Related Posts
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Checkpoint inhibitors show promise as second-line salvage therapy in advanced Hodgkin lymphoma, per Philippe Armand, MD, PhD
Sankalp Arora, MBBS, a second-year fellow at MD Anderson, presented data on FLT3 inhibitors in AML at the HemOnc Pulse Live.
Ryan Jacobs, MD discusses 2025 CLL treatment advances, including BTK/BCL-2 combos, resistance, and time-defined strategies.
Results from the phase 1b study suggest venetoclax plus modified chemotherapy is an effective and well-tolerated approach.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.